Literature DB >> 12828568

The enteric nervous system III: a target for pharmacological treatment.

Mark Berner Hansen1.   

Abstract

The past decade has seen major advances in the pharmacological understanding of the nervous system of the gastrointestinal tract, the enteric nervous system, and its importance for gut functions in several states of disease. Indeed, the enteric nervous system has become a promising target in the treatment of many gastrointestinal symptoms and disorders. Some of these new therapeutic concepts, such as botulinum toxin for achalasia and serotonergic drugs for functional bowel diseases, are already in clinical use. This paper is part 3 of three Minireviews in Pharmacology & Toxicology, and presents the neurogastrointestinal pharmacological therapeutic options in gastrointestinal pain, functional gastrointestinal disorders, inflammatory bowel diseases, cancer and related conditions with focus on future drug targets. The diagnosis of gastrointestinal neuropathy, the role of serotonin and related neuroendocrine transmitters, serotonergic drugs, and neurotrophic factors in neurogastrointestinal pharmacology will be addressed in this context.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12828568     DOI: 10.1034/j.1600-0773.2003.930101.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  12 in total

1.  Altered responsiveness of the guinea-pig isolated ileum to smooth muscle stimulants and to electrical stimulation after in situ ischemia.

Authors:  Rodolfo Rodriguez; Rosa Ventura-Martinez; Jacinto Santiago-Mejia; Maria R Avila-Costa; Teresa I Fortoul
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 2.  Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies.

Authors:  Gerardo Gutiérrez-Gutiérrez; María Sereno; Ambrosio Miralles; Enrique Casado-Sáenz; Eduardo Gutiérrez-Rivas
Journal:  Clin Transl Oncol       Date:  2010-02       Impact factor: 3.405

3.  Gastrointestinal Uses of Botulinum Toxin.

Authors:  Maria Cariati; Maria Michela Chiarello; Marco Cannistra'; Maria Antonietta Lerose; Giuseppe Brisinda
Journal:  Handb Exp Pharmacol       Date:  2021

Review 4.  Botulinum toxins--cause of botulism and systemic diseases?

Authors:  H Böhnel; F Gessler
Journal:  Vet Res Commun       Date:  2005-05       Impact factor: 2.459

5.  5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells.

Authors:  M Yasuda; S Kato; N Yamanaka; M Iimori; K Matsumoto; D Utsumi; Y Kitahara; K Amagase; S Horie; K Takeuchi
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

Review 6.  Role of serotonin in the pathophysiology of the irritable bowel syndrome.

Authors:  Michael D Crowell
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

7.  5-HT3 receptors promote colonic inflammation via activation of substance P/neurokinin-1 receptors in dextran sulphate sodium-induced murine colitis.

Authors:  Daichi Utsumi; Kenjiro Matsumoto; Kikuko Amagase; Syunji Horie; Shinichi Kato
Journal:  Br J Pharmacol       Date:  2016-04-21       Impact factor: 8.739

8.  Visceral hypersensitivity following cold water intake in subjects with irritable bowel syndrome.

Authors:  Xiu Li Zuo; Yan Qing Li; Lei Shi; Guo Ping Lv; Rong Guang Kuang; Xue Feng Lu; Jun Man Li; Paul V Desmond
Journal:  J Gastroenterol       Date:  2006-04       Impact factor: 6.772

9.  Human adult stem cells derived from adipose tissue and bone marrow attenuate enteric neuropathy in the guinea-pig model of acute colitis.

Authors:  Rhian Stavely; Ainsley M Robinson; Sarah Miller; Richard Boyd; Samy Sakkal; Kulmira Nurgali
Journal:  Stem Cell Res Ther       Date:  2015-12-10       Impact factor: 6.832

10.  Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome.

Authors:  Toshimi Chiba; Kazunari Yamamoto; Shoko Sato; Kazuyuki Suzuki
Journal:  Clin Exp Gastroenterol       Date:  2013-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.